Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

Associations of Clinical and Dosimetric Parameters with Urinary Toxicities after Prostate Brachytherapy: A Long-Term Single-Institution Experience

Version 1 : Received: 18 May 2023 / Approved: 22 May 2023 / Online: 22 May 2023 (16:28:32 CEST)

A peer-reviewed article of this Preprint also exists.

Ito, M.; Makita, C.; Mori, T.; Takano, H.; Kumano, T.; Matsuo, M.; Iinuma, K.; Kawase, M.; Nakane, K.; Nakano, M.; Koie, T. Associations of Clinical and Dosimetric Parameters with Urinary Toxicities after Prostate Brachytherapy: A Long-Term Single-Institution Experience. Curr. Oncol. 2023, 30, 5680-5689. Ito, M.; Makita, C.; Mori, T.; Takano, H.; Kumano, T.; Matsuo, M.; Iinuma, K.; Kawase, M.; Nakane, K.; Nakano, M.; Koie, T. Associations of Clinical and Dosimetric Parameters with Urinary Toxicities after Prostate Brachytherapy: A Long-Term Single-Institution Experience. Curr. Oncol. 2023, 30, 5680-5689.

Abstract

To examine the association of clinical, treatment, and dose parameters with late urinary toxicity after low-dose-rate brachytherapy (LDR-BT) for prostate cancer, we retrospectively studied patients with prostate cancer who underwent LDR-BT from January 2007 through December 2016. Urinary toxicity was assessed using the International Prostate Symptom Score (IPSS) and Overactive Bladder (OAB) Symptom Score (OABSS). Severe and moderate lower urinary tract symptoms (LUTS) were defined as IPSS ≥ 20 and ≥ 8, respectively; OAB was defined as a nocturnal frequency of ≥ 2 and a total OABSS of ≥ 3. In total, 203 patients (median age, 66 years) were included, with a mean follow-up of 8.4 years after treatment. The IPSS and OABSS worsened after 3 months of treatment; these scores improved to pretreatment levels after 18–36 months in most patients. Patients with a higher baseline IPSS and OABSS had a lower frequency of moderate and severe LUTS and OAB at 24 and 60 months, respectively. LUTS and OAB at 24 and 60 months were not correlated with the dosimetric factors of LDR-BT. Although the rate of long-term urinary toxicities assessed using IPSS and OABSS was low, the baseline scores were related to long-term function. Refining patient selection may further reduce long-term urinary toxicity.

Keywords

prostate cancer; brachytherapy; lower urinary tract symptom; international prostate symptom score (IPSS); overactive bladder symptom score (OABSS)

Subject

Medicine and Pharmacology, Urology and Nephrology

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.